Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus EXTREME regimen for first-line recurrent or metastatic head and neck squamous cell carcinoma
jRCT2080223334Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Ono Pharmaceutical. Started Sep 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080223334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223334.